UNITED THERAPEUTICS Corp (UTHR) shareholders
Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 5,294,844 | 11.30% | 13G (passive) amendment | Dec 31, 2023 |
| Behzad Aghazadeh Joint filing with Avoro Capital Advisors LLC (6.10%) | 2,858,888 | 6.10% | 13G (passive) amendment | Dec 31, 2023 |
| Wellington Investment Advisors Holdings LLP Joint filing with Wellington Management Group LLP (5.50%), Wellington Group Holdings LLP (5.50%) | 2,463,891 | 5.50% | 13G (passive) amendment | Dec 31, 2024 |
| Wellington Group Holdings LLP Joint filing with Wellington Management Group LLP (5.70%), Wellington Investment Advisors Holdings LLP (5.70%) | 2,441,492 | 5.70% | 13G (passive) | Dec 31, 2025 |
| Rothblatt Martine A | 2,333,721 | 5.30% | 13G (passive) amendment | Jun 30, 2026 |
| Vanguard Capital Management | 2,278,348 | 5.19% | 13G (passive) | Mar 31, 2026 |
| United Therapeutics Corporation | 1 | 100.00% | 13D (active) | Dec 12, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of UTHR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,294,529 | 12.34% | $2.87B | −105,120 | 0.04% |
| Avoro Capital Advisors LLC | 2,777,777 | 6.48% | $1.51B | +147,777 | 13.52% |
| Vanguard Portfolio Management LLC | 1,919,429 | 4.48% | $1.04B | −84,313 | 0.05% |
| Vanguard Capital Management LLC | 1,918,256 | 4.47% | $1.04B | −39,283 | 0.02% |
| State Street Corp | 1,898,064 | 4.43% | $1.03B | +54,101 | 0.03% |
| Renaissance Technologies LLC | 1,708,739 | 3.98% | $925.85M | −78,280 | 1.27% |
| Wellington Management Group Llp | 1,379,025 | 3.22% | $747.20M | −885,222 | 0.13% |
| Geode Capital Management, LLC | 996,598 | 2.32% | $538.86M | −236,431 | 0.03% |
| Jupiter Topco LLC | 831,129 | 1.94% | $450.14M | New | 0.18% |
| Norges Bank | 694,753 | 1.62% | $376.44M | New | 0.04% |
| Assetmark, Inc | 624,068 | 1.46% | $338.14M | +8,018 | 0.58% |
| Aqr Capital Management LLC | 546,002 | 1.27% | $294.64M | −280,224 | 0.10% |
| Dimensional Fund Advisors LP | 527,904 | 1.23% | $286.05M | +15,165 | 0.05% |
| FMR LLC | 473,409 | 1.10% | $256.51M | −54,937 | 0.01% |
| Invesco Ltd. | 473,109 | 1.10% | $256.34M | −135,258 | 0.02% |
| Baillie Gifford & Co | 467,209 | 1.09% | $253.15M | +39,082 | 0.23% |
| Deerfield Management Company, L.P. (Series C) | 457,000 | 1.07% | $247.62M | – | 2.58% |
| Morgan Stanley | 436,699 | 1.02% | $236.62M | +27,411 | 0.01% |
| Vestal Point Capital, LP | 435,000 | 1.01% | $235.70M | +360,000 | 5.51% |
| Northern Trust Corp | 430,844 | 1.00% | $233.44M | −5,722 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 878 | 42M | 97.4% | 107 / 317 | 331 / 70 | 5M | 4M |
| Q1 2026 | 854 | 42M | 96.8% | 114 / 301 | 322 / 86 | 8M | 4M |
| Q4 2025 | 837 | 42M | 98.3% | 201 / 281 | 259 / 54 | 7M | 5M |
| Q3 2025 | 708 | 41M | 96.1% | 112 / 212 | 286 / 66 | 5M | 7M |
| Q2 2025 | 671 | 44M | 100.0% | 77 / 283 | 220 / 71 | 4M | 5M |
| Q1 2025 | 672 | 45M | 100.0% | 91 / 255 | 229 / 81 | 4M | 3M |
| Q4 2024 | 673 | 44M | 100.0% | 104 / 269 | 211 / 45 | 3M | 3M |
| Q3 2024 | 626 | 44M | 100.0% | 112 / 205 | 228 / 48 | 9M | 5M |
| Q2 2024 | 568 | 46M | 100.0% | 105 / 200 | 195 / 55 | 6M | 6M |
| Q1 2024 | 524 | 47M | 100.0% | 55 / 214 | 182 / 61 | 6M | 5M |
| Q4 2023 | 535 | 45M | 100.0% | 78 / 202 | 169 / 41 | 4M | 3M |
| Q3 2023 | 508 | 45M | 100.0% | 72 / 174 | 180 / 34 | 2M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
654 funds held UTHR in Q2 2026, 60% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of UTHR | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 1,452,598 | 3.39% | $787.06M | 0.63% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,347,720 | 3.14% | $730.24M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 973,490 | 2.27% | $527.47M | 0.28% | Jun 30, 2026 |
| Vanguard Health Care Fund | 719,385 | 1.68% | $372.43M | 0.98% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 486,555 | 1.13% | $263.63M | 0.27% | Jun 30, 2026 |
| Vanguard Small-Cap Value Index Fund | 308,328 | 0.72% | $167.06M | 0.25% | Jun 30, 2026 |
| Vanguard U.S. Growth Fund | 304,130 | 0.71% | $169.35M | 0.36% | May 31, 2026 |
| iShares Biotechnology ETF | 290,800 | 0.68% | $157.56M | 1.73% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 280,758 | 0.65% | $152.12M | 0.32% | Jun 30, 2026 |
| Invesco S&P MidCap Quality ETF | 266,163 | 0.62% | $137.80M | 2.53% | Jul 31, 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 253,957 | 0.59% | $137.60M | 1.22% | Jun 30, 2026 |
| Franklin Dynatech Fund | 225,000 | 0.52% | $121.91M | 0.40% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 221,883 | 0.52% | $123.55M | 0.29% | May 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF | 214,879 | 0.50% | $116.43M | 0.63% | Jun 30, 2026 |
| Fullerthaler Behavioral Small Cap Equity | 204,471 | 0.48% | $110.79M | 0.88% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Martine A. Rothblatt | Chairperson & CEO, Director | 365,122 | 0.85% | Nov 17, 2026 |
| Paul A. Mahon | EVP & GENERAL COUNSEL | 45,172 | 0.11% | Nov 5, 2026 |
| James Edgemond | CFO AND TREASURER | 25,506 | 0.06% | Jun 23, 2026 |
| Michael Benkowitz | PRESIDENT AND COO | 36,462 | 0.09% | May 14, 2026 |
| Christopher Patusky | Director | 3,240 | 0.01% | Nov 10, 2026 |
| Nilda Mesa | Director | 5,580 | 0.01% | Sep 15, 2026 |
| Tommy G. Thompson | Director | 22,480 | 0.05% | Jul 23, 2026 |
| Judy D. Olian | Director | 5,555 | 0.01% | Jul 23, 2026 |
| Kevin Tracey | Director | – | – | Jul 23, 2026 |
| Jan Malcolm | Director | 450 | 0.00% | Jul 23, 2026 |
| Linda Maxwell | Director | 2,000 | 0.00% | Jul 23, 2026 |
| Christopher Causey | Director | 4,190 | 0.01% | Jul 23, 2026 |
| Louis W. Sullivan | Director | 4,440 | 0.01% | Jul 23, 2026 |
| Ray Kurzweil | Director | 13,320 | 0.03% | Jul 23, 2026 |
| Victor J. Dzau | Director | – | – | Jul 23, 2026 |
| Richard Giltner | Director | 21,884 | 0.05% | Jul 23, 2026 |
| Raymond Dwek | Director | 4,750 | 0.01% | Jul 28, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −120 | $595.19 | $71.42K | 324,443 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −200 | $594.60 | $118.92K | 324,563 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −240 | $593.16 | $142.36K | 324,763 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −514 | $592.05 | $304.31K | 325,003 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −996 | $591.26 | $588.89K | 325,517 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −575 | $590.25 | $339.39K | 326,513 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −835 | $588.59 | $491.47K | 327,088 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −1,090 | $587.61 | $640.49K | 327,923 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −2,108 | $586.72 | $1.24M | 329,013 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −1,382 | $585.83 | $809.62K | 331,121 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −640 | $584.54 | $374.10K | 332,503 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −240 | $583.61 | $140.07K | 333,143 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −280 | $582.18 | $163.01K | 333,383 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −170 | $581.25 | $98.81K | 333,663 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Sale(10b5-1 plan) | −110 | $580.25 | $63.83K | 333,833 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 16, 2026 | Option exercise | +9,500 | $117.76 | $1.12M | 333,943 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −40 | $598.83 | $23.95K | 324,443 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −440 | $597.48 | $262.89K | 324,483 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −480 | $596.65 | $286.39K | 324,923 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −1,040 | $595.41 | $619.23K | 325,403 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −1,275 | $594.65 | $758.18K | 326,443 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −245 | $593.81 | $145.48K | 327,718 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −518 | $592.61 | $306.97K | 327,963 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −2,181 | $591.56 | $1.29M | 328,481 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −1,657 | $590.65 | $978.70K | 330,662 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −603 | $589.80 | $355.65K | 332,319 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −493 | $588.61 | $290.18K | 332,922 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −528 | $587.42 | $310.16K | 333,415 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 13, 2026 | Option exercise | +9,500 | $117.76 | $1.12M | 333,943 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −280 | $597.33 | $167.25K | 324,443 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −662 | $596.22 | $394.70K | 324,723 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −1,409 | $595.17 | $838.59K | 325,385 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −3,079 | $594.24 | $1.83M | 326,794 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −1,934 | $593.44 | $1.15M | 329,873 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −551 | $592.32 | $326.37K | 331,807 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −317 | $591.10 | $187.38K | 332,358 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −359 | $590.11 | $211.85K | 332,675 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −427 | $589.21 | $251.59K | 333,034 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −323 | $588.30 | $190.02K | 333,461 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −159 | $587.00 | $93.33K | 333,784 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 12, 2026 | Option exercise | +9,500 | $117.76 | $1.12M | 333,943 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −247 | $598.63 | $147.86K | 324,443 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −1,299 | $597.61 | $776.30K | 324,690 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −1,324 | $596.74 | $790.08K | 325,989 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −1,346 | $595.46 | $801.48K | 327,313 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −991 | $594.66 | $589.31K | 328,659 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −961 | $593.57 | $570.42K | 329,650 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −1,172 | $592.68 | $694.63K | 330,611 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −736 | $591.56 | $435.39K | 331,783 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −301 | $590.31 | $177.68K | 332,519 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −292 | $589.18 | $172.04K | 332,820 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −271 | $588.16 | $159.39K | 333,112 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −320 | $586.59 | $187.71K | 333,383 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −215 | $585.93 | $125.98K | 333,703 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Sale(10b5-1 plan) | −25 | $584.20 | $14.61K | 333,918 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 11, 2026 | Option exercise | +9,500 | $117.76 | $1.12M | 333,943 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 10, 2026 | Sale(10b5-1 plan) | −80 | $592.93 | $47.43K | 324,443 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 10, 2026 | Sale(10b5-1 plan) | −120 | $592.20 | $71.06K | 324,523 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 10, 2026 | Sale(10b5-1 plan) | −960 | $590.95 | $567.32K | 324,643 |
| Martine A. Rothblatt Chairperson & CEO, Director | Nov 10, 2026 | Sale(10b5-1 plan) | −2,040 | $589.95 | $1.20M | 325,603 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of United Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,582 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Christopher Patusky Director | Nov 9, 2026 | 1,210 | $701.80K | Nov 9, 2026 | Stock Option Exercise |
| Paul A. Mahon Officer | Nov 5, 2026 | 8,300 | $4.97M | Nov 5, 2026 | Stock Option Exercise |
| Martine A. Rothblatt Director, Officer | Nov 2, 2026 | 119,410 | $71.49M | Nov 2, 2026 | Exercise of Stock Options |
| Paul A. Mahon Officer | Oct 15, 2026 | 8,300 | $4.52M | Oct 15, 2026 | Stock Option Exercise |
| Martine A. Rothblatt Director, Officer | Oct 1, 2026 | 209,000 | $113.26M | Oct 1, 2026 | Exercise of Stock Options |
| Paul A. Mahon Officer | Oct 1, 2026 | 8,300 | $4.69M | Oct 1, 2026 | Stock Option Exercise |
| Paul A. Mahon Officer | Sep 17, 2026 | 8,300 | $4.13M | Sep 17, 2026 | Stock Option Exercise |
| Nilda Mesa Director | Sep 14, 2026 | 228 | $115.34K | Sep 14, 2026 | Stock Option Exercise |
| Paul A. Mahon Officer | Sep 3, 2026 | 8,300 | $4.00M | Sep 3, 2026 | Stock Option Exercise |
| Martine A. Rothblatt Officer | Sep 1, 2026 | 199,500 | $101.82M | Sep 1, 2026 | Exercise of Stock Options |
| Paul A. Mahon Officer | Aug 20, 2026 | 8,300 | $4.34M | Aug 20, 2026 | Stock Option Exercise |
| Paul A. Mahon Officer | Aug 6, 2026 | 8,300 | $4.29M | Aug 6, 2026 | Stock Option Exercise |
| Martine A. Rothblatt Director, Officer | Aug 3, 2026 | 199,500 | $103.28M | Aug 3, 2026 | Exercise of Stock Options |
| Paul A. Mahon Officer | Jul 16, 2026 | 8,300 | $4.43M | Jul 16, 2026 | Stock Option Exercise |
| Jan Malcolm Director | Jul 10, 2026 | 325 | $178.94K | Jul 10, 2026 | Restricted Stock |
Congress trades
7 trades in United Therapeutics reported by 3 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Lisa McClain MI09 · spouse | Sold | Oct 31, 2025 | $1K–15K | Nov 21, 2025 |
| Lisa McClain MI09 · spouse | Sold | Oct 30, 2025 | $1K–15K | Nov 21, 2025 |
| Lisa McClain MI09 · spouse | Bought | Oct 30, 2025 | $1K–15K | Nov 21, 2025 |
| Lisa McClain MI09 · spouse | Bought | Jun 11, 2025 | $1K–15K | Aug 13, 2025 63 days late |
| Michael T. McCaul TX10 · child | Bought | Jun 18, 2021 | $1K–15K | Jul 16, 2021 |
| Michael T. McCaul TX10 · child | Bought | Jun 9, 2021 | $1K–15K | Jul 16, 2021 |
| Thomas MacArthur NJ03 · joint account | Sold | May 27, 2015 | $1K–15K | Jun 7, 2015 |
See a number that looks wrong?